Apoptosis and cancer chemotherapy

Cell and Tissue Research

Volumn 301, Issue 1, 2000, Pages 143-152

  Makin, Guy ^a   Hickman, John A ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Apoptosis; Bcl 2 family; Chemotherapy; Drug resistance; P53

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PROTEIN; DNA; FAS ANTIGEN; INTERLEUKIN 3; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; APOPTOSIS; CANCER CHEMOTHERAPY; CELL ACTIVATION; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; DRUG RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; GENOTOXICITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0033927677     PISSN: 0302766X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004419900160     Document Type: Review

References (102)

1. Adams JM, Cory S (1998) The Bcl-2 protein family: arbiters of cell survival. Science 281:1322-1326
2. Bellamy COC (1997) p53 and apoptosis. Br Med Bull 53:522-538
3. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE (1998) Stat 3 activation is required for cellular transformation by v-src. Mol Cell Biol 18:2553-2558
4. Brown JM, Wouters BG (1999a) Apoptosis, p53, and tumour cell sensitivity to anticancer agents. Cancer Res 59:1391-1399
5. Brown JM, Wouters BG (1999b) Does apoptosis contribute to tumour cell sensitivity to anticancer agents? In: Hickman JA, Dive C (eds) Apoptosis and cancer chemotherapy. Humana Press, Totowa, New Jersey, pp 1-19
6. Brown R (1997) The Bcl-2 family of proteins. Br Med Bull 53:466-477
7. Brunet CL, Gunby RH, Benson RSP, Hickman JA, Watson AJM, Brady G (1998) Commitment to cell death measured by loss of clonogenicity is separable from the appearance of apoptotic markers. Cell Death Differ 5:107-115
8. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree R, Muss HB, Green MR, Norton L, Frei E (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90:1205-1211
9. Caelles C, Helmberg A, Karin M (1994) p53 dependent apoptosis in the absence of transcriptional activation of p53 target genes. Nature 370:220-223
10. Campbell SJ, O'Neill M, Hall PA (1999) Function of the p53 gene family: a holistic perspective. In: Hickman JA, Dive C (eds) Apoptosis and cancer chemotherapy. Humana Press, Totowa, New Jersey, pp 53-68
11. Canman CE, Chen CY, Lee MH, Kastan MB (1994) DNA-damage responses - p53 induction, cell-cycle perturbations, and apoptosis. Cold Spring Harb Symp Quant Biol 59:277-286
12. Cartwright C (1998) Intestinal cell growth control: role of Src tyrosine kinase. Gastroenterology 114:1335-1338
13. Chen CY, Oliner JD, Zhan QM, Fornace AJ, Vogelstein B, Kastan MB (1994) Interactions between p53 and mdm2 in a mammalian-cell cycle checkpoint pathway. Proc Natl Acad Sci U S A 91:2684-2688
14. Chen-Leavy S, Cleary ML (1990) Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro. J Biol Chem 265:4929-2933
15. Chinnaiyan AM (1999) The apoptosome: heart and soul of the cell death machine. Neoplasia 1:5-15
16. Chittendon T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, Chinnadurai G, Lutz RJ (1995) A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J 14:5589-5596
17. Chresta CM, Masters JRW, Hickman JA (1996) Hypersensitivity of human testicular-tumours to etoposide-induced apoptosis is associated with functional p53 and a high Bax-Bcl-2 ratio. Cancer Res 56:1834-1841
18. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852
19. Cox LS (1997) Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21 (Cip1/WAF1/Sdi1). J Pathol 183:134-140
20. Datta SR, Dudek H, Tao X, Masters S, Fu HA, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell intrinsic death machinery. Cell 91:231-241
21. Deng CX, Zhang PM, Harper JW, Elledge SJ, Leder P (1995) Mice lacking p21(Cip1/waf1) undergo normal development, but are defective in G1 checkpoint control. Cell 82:675-684
22. Desagher S, OsenSand A, Nichols A, Eskes R, Montessuit S, Lauper S, Maundrell K, Antonsson B, Martinou JC (1999) Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144:891-901
23. Dive C, Hickman JA (1991) Drug-target interactions: only the first step in the commitment to programmed cell death? Br J Cancer 64:192-196
24. Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10:262-267
25. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B (1993) Waf1, a potential mediator of p53 tumour suppression. Cell 75:817-825
26. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill DE, Wang YS, Wiman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B (1994) Waf1/Cip1 is induced in p53-mediated G(1) arrest and apoptosis. Cancer Res 54:1169-1174
27. Farrow SF, White JHM, Martinou I, Raven T, Pun K-T, Grinham CJ, Martinou J-C, Brown R (1995) Cloning of a Bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 374: 731-733
28. Fisher DE (1994) Apoptosis in cancer-therapy - crossing the threshold. Cell 78:539-542
29. Friesen C, Herr I, Debatin K-M, Krammer PH (1996) Involvement of the CD95 (Apo-1/Fas) receptor-ligand system in drug induced apoptosis in leukaemia cells. Nature Med 2:574-577
30. Fulda S, Los M, Friesen C, Debatin K-M (1998) Chemosensitivity of solid tumour cells in vitro is related to the activation of the CD95 system. Int J Cancer 76:105-114
31. Glaser T, Wagenknecht B, Groscurth P, Krammer PH, Weller M (1999) Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells. Oncogene 18:5044-5053
32. Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, Korsmeyer SJ, Shore GC (1998) Regulated targeting of BAX to mitochondria. J Cell Biol 143:207-215
33. Graeber AJ, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Graccia AJ (1996) Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91
34. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumour-suppressor gene - clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878
35. Griffiths GJ, Dubrez L, Jones NH, Morgan CP, Whitehouse J, Corfe BM, Dive C, Hickman JA (1999) Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 144:903-914
36. Gross A, Jockel J, Wei MC, Korsmeyer SJ (1998) Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 17:3878-3885
37. Haldar S, Jena N, Croce CM (1995) Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A 92:4507-4511
38. Harada HBB, Wilm M, Mann M, Huang LJ, Taylor SS, Scott JD, Korsmeyer SJ (1999) Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Molec Cell 3:413-422
39. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 cdk-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816
40. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang PM, Dobrowolski S, Bai C, Connellcrowley L, Swindell E, Fox MP, Wei N (1995) Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387-400
41. Harrington EA, Bennett MR, Fanidi A, Evan GI (1994) c-myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13:3286-3295
42. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299
43. Hawkins DS, Demers GW, Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898
44. Hengartner MO (1998) Death cycles and Swiss army knifes. Nature 391:441-442
45. Hickman JA (1995) Apoptosis - its role in drug-sensitivity and resistance. Eur J Cancer 31A:7-7
46. Hickman JA (1996) Apoptosis and chemotherapy resistance. Eur J Cancer 32A:921-926
47. Hickman JA, Dive C (1999) Apoptosis and cancer chemotherapy, vol 5. Humana Press, Totowa, New Jersey
48. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ (1990) Bcl-2 is an inner mitochondrial-membrane protein that blocks programmed cell-death. Nature 348:334-336
49. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49-53
50. Huang LC, Clarkin KC, Wahl GM (1996) Sensitivity and selectivity of the DNA damage sensor responsible for activating p53 dependent G1 arrest. Proc Natl Acad Sci U S A 93:4827-4832
51. Kastan MB (1996) Signalling to p53 - where does it all start. Bioessays 18:617-619
52. Kerr JFR, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239-257
53. Knudson CM, Korsmeyer SJ (1997) Bcl-2 and Bax function independently to regulate cell death. Nature Genet 16:285-291
54. Knudson CM, Tung KSM, Tourtellotte WG, Brown GAJ, Korsmeyer SJ (1995) Bax deficient mice with lymphoid hyperplasia and male germ cell death. Science 270:96-99
55. Kubbutat MHG, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303
56. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323-331
57. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alremri ES, Wang XD (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase 9 complex. Cell 91:479-489
58. Linke SP, Clarkin KC, DiLeonardo A, Tsou A, Wahl GM (1996) A reversible, p53 dependent G0/G1 arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 10:934-947
59. Lowe SW, Ruley HE, Jacks T, Housman DE (1993a) p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967
60. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993b) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849
61. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 status and the efficacy of cancer-therapy in vivo. Science 266:807-810
62. McCurrach ME, Connor TMF, Knudson CM, Korsmeyer SJ, Lowe SW (1997) Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci U S A 94:2345-2349
63. Merritt AJ, Potten CS, Watson AJM, Loh DY, Nakayama K, Hickman JA (1995) Differential expression of Bcl-2 in intestinal epithelia: correlation with attenuation of apoptosis in colonic crypts and the incidence of colonic neoplasia. J Cell Sci 108:2261-2271
64. Merritt AJ, Allen TD, Potten CS, Hickman JA (1997) Apoptosis in small intestinal epithelia from p53 -null mice: evidence for a delayed, p53-independent G2/M-associated cell death after γ-irradiation. Oncogene 14:2759-2766
65. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT (1997) Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 89: 783-789
66. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D (1994) Induction of waf1/cip1 by a p53-independent pathway. Cancer Res 54:3391-3395
67. Miyashita T, Reed JC (1995) Tumour-suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299
68. L, an inhibitor of programmed cell death. Nature 381:335-341
69. Oliner JD, Pietenpol JA, Thiagalingam S, Gvuris J, Kinzler KW, Vogelstein B (1993) Oncoprotein mdm2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860
70. Oltvai ZN, Milliman CL, Korsmeyer SJ (1993) Bcl-2 heterodime-rises in vivo with a conserved homologue, Bax, that accelerates programmed cell death. Cell 74:609-619
71. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389:300-305
72. Potten CS (1996) What is an apoptotic index measuring? A commentary. Br J Cancer 74:1743-1748
73. Prives C, Hall PA (1999) The p53 pathway. J Pathol 187:98-116
74. Raff MC (1993) Social controls on cell survival and cell death. Nature 356:397-400
75. Reed JC (1997) Double identity for proteins of the Bcl-2 family. Nature 387:773-776
76. Reed JC (1999) Bcl-2 family proteins: relative importance as determinants of chemoresistance in cancer. In: Hickman JA, Dive C (eds) Apoptosis and cancer chemotherapy. Humana Press, Totowa, New Jersey, pp 99-116
77. Rosse T, Olivier R, Monney L, Rayer M, Conus S, Fellay I, Janson B, Borner C (1998) Bcl-2 prolongs cell survival after Bax induced release of cytochrome c. Nature 391:496-499
78. Ruan S, Okcu MF, Ren JP, Chiao P, Andreeff M, Levin V, Zhang W (1998) Overexpressed WAF1/Cip1 renders glioblastoma cells resistant to chemotherapy agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin. Cancer Res 58:1538-1543
79. Scaffidi C, Fulda S, Li F, Friesen C, Srinivasan A, Tomaselli KJ, Debatin K-M, Krammer PH, Peter ME (1998) Two CD95 signalling pathways. EMBO J 17:1675-1687
80. Shieh SY, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334
81. L and Bax by tumour microenvironmental factors. J Natl Cancer Inst 92:18-23
82. Tlsty TD (1997) Genomic instability and its role in neoplasia. Current topics in microbiology and immunology, vol 221. Springer, Berlin Heidelberg New York, pp 37-46
83. Traxler P, Furet P (1999) Strategies towards the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 82:195-206
84. Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 83:5214-5218
85. Vaux D, Cory S, Adams J (1988) Bcl-2 gene promotes haematopoietic cell survival and co-operates with c-myc to immortalize pre-B cells. Nature 335:440-442
86. Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R (1997) Drug-induced apoptosis is associated with enhanced Fas (APO-1/CD95) ligand expression but occurs independently of Fas (APO-1/CD95) signaling in human T-acute lymphatic leukaemia cells. Cancer Res 57:3331-3334
87. Waga S, Hannon GJ, Beach D, Stillman B (1994) The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369:574-578
88. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW, Galloway DA (1996) Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med 2:72-79
89. Waldman T, Kinzler KW, Vogelstein B (1995) p21 is necessary for the p53-mediated G(1) arrest in human cancer cells. Cancer Res 55:5187-5190
90. Waldman T, Lengauer C, Kinzler KW, Vogelstein B (1996) Uncoupling of S-phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713-716
91. Waldman T, Zhang YG, Dillehay L, Yu J, Kinzler K, Vogelstein B, Williams J (1997) Cell-cycle arrest versus cell death in cancer therapy. Nature Med 3:1034-1036
92. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolmwini JK, Van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevity DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes KE, Paull KD (1997) An information intensive approach to the molecular pharmacology of cancer. Science 275:343-349
93. Wolter KG, Hsu Y-T, Smith CL, Nechushtan A, Xi X-G, Youle RJ (1997) Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139:1281-1293
94. Wouters BG, Giaccia AJ, Denko NC, Brown JM (1997) Loss of p21(Waf1/Cip1) sensitizes tumours to radiation by an apoptosis-independent mechanism. Cancer Res 57:4703-4706
95. Wu GS, El-Deiry WS (1996) p53 and chemosensitivity. Nature Med 2:255-256
96. Wyllie AH (1987) Apoptosis - cell-death in tissue regulation. J Pathol 153:313-316
97. Yin CK, Knudson CM, Korsmeyer SJ, Van Dyke T (1997) Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385:637-640
98. Zamzami N, Brenner C, Marzo I, Susin SA, Kroemer G (1998) Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 16:2265-2282
99. Zeng YX, El-Deiry WS (1996) Regulation of p21(Waf1/Cip1) expression by p53-independent pathways. Oncogene 12:1557-1564
100. L. Cell 87:619-628
101. Zhivotovsky B, Orrenius S, Brustugan OT, Doskeland SO (1998) Injected cytochrome c induces apoptosis. Nature 391:449-450
102. Zou H, Henzel WJ, Liu XS, Lutschg A, Wang XD (1997) Apaf-1, a human protein homologous to C. elegans CED4, participates in cytochrome c dependent activation of caspase 3. Cell 90:405-413